[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 28, 1999

Treatment of Attention-Deficit/Hyperactivity Disorder

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;281(16):1490-1491. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-16-jbk0428

To the Editor: The AMA Council on Scientific Affairs1 reasoned that review of the treatment and diagnosis of ADHD is of timely importance, as the authors rightly note that there is a public "climate of fear among physicians, parents, and educators" about treatment with psychostimulants, despite the clear efficacy these medications offer. It is, for this reason, surprising to find that the authors failed to mention that methamphetamine is also a US Food and Drug Administration–approved treatment for ADHD. No data exist that prescribed methamphetamine is more likely to be abused than methylphenidate or d-amphetamine. Methamphetamine is also regarded as having more potent centrally acting properties and less potent peripherally acting properties than d-amphetamine.2 With the longest duration of action of any of the stimulants (8-12 hours), methamphetamine has the advantage of offering true once-a-day dosing. In addition, methamphetamine still has a limited role in the treatment of obesity, has antidepressant properties,3 and is an effective treatment for narcolepsy.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×